Notably, the U.S. Food and Drug Administration approved several anti-obesity drugs, including Orlistat (which inhibits the enzyme FAS and the pancreatic lipases), Phentermine/Topiramate, Naltrexone/Bupropion, Liraglutide, Semaglutide, Setmelanotide, and Tirzepatide [107]. Here, FAS is linked to obesity due to melanocortin 4 receptor deficiency.